Patents Represented by Attorney, Agent or Law Firm Hugh Wang
-
Patent number: 8268817Abstract: Certain oxazole ketone compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: GrantFiled: September 7, 2007Date of Patent: September 18, 2012Assignee: The Scripps Research InstituteInventor: Dale L. Boger
-
Patent number: 8252902Abstract: The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.Type: GrantFiled: October 22, 2002Date of Patent: August 28, 2012Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Christoph Rader, Subhash C. Sinha, Richard A. Lerner
-
Patent number: 8039690Abstract: Clusters of plant genes that are regulated in response to one or more stress conditions are provided, as are isolated plant stress-regulated genes, including portions thereof comprising a coding sequence or a regulatory element, and to consensus sequences comprising a plant stress-regulated regulatory element. In addition, a recombinant polynucleotide, which includes a plant stress-regulated gene, or functional portion thereof, operatively linked to a heterologous nucleotide sequence, is provided, as are transgenic plants, which contain a plant stress-regulated gene or functional portion thereof that was introduced into a progenitor cell of the plant. Also provided are methods of using a plant stress-regulated gene to confer upon a plant a selective advantage to a stress condition, methods of identifying an agent that modulates the activity of a plant stress-regulated regulatory element, and methods of determining whether a plant has been exposed to a stress.Type: GrantFiled: March 18, 2009Date of Patent: October 18, 2011Assignee: The Scripps Research InstituteInventors: Jeffrey F. Harper, Joel Kreps, Xun Wang, Tong Zhu
-
Patent number: 7985841Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.Type: GrantFiled: December 22, 2005Date of Patent: July 26, 2011Assignee: The Scripps Research InstituteInventors: Angray Kang, Carlos F. Barbas, Richard A. Lerner
-
Patent number: 7863241Abstract: The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.Type: GrantFiled: October 22, 2004Date of Patent: January 4, 2011Assignee: The Scripps Research InstituteInventor: Charles G. Cochrane
-
Patent number: 7807817Abstract: The present invention discloses nucleic acid enzymes and deoxyribonucleic acid enzymes capable of cleaving nucleic acid sequences or molecules, particularly RNA, in a site-specific manner, as well as compositions including same. Methods of making and using the disclosed enzymes and compositions are also disclosed.Type: GrantFiled: November 28, 2006Date of Patent: October 5, 2010Assignee: The Scripps Research InstituteInventors: Gerald F. Joyce, Ronald R. Breaker
-
Patent number: 7732150Abstract: Lambdoid phage comprising a matrix of proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a lambdoid phage tail protein matrix anchor domain fused to at least one of the polypeptides.Type: GrantFiled: March 3, 2005Date of Patent: June 8, 2010Assignee: The Scripps Research InstituteInventors: Ichiro Maruyama, Hiroko Maruyama, Sydney Brenner
-
Patent number: 7705199Abstract: Compositions and methods are provided for treatment of autoimmune and other related diseases. 3d, a point mutation of the protein uncoordinated-93b (unc-93B), unc-93A, unc-93B, and unc-93C, polypeptides, nucleic acids encoding them and methods for making and using them, for example, to produce transgenic non-human animals.Type: GrantFiled: March 2, 2006Date of Patent: April 27, 2010Assignee: The Scripps Research InstituteInventors: Bruce Beutler, Koichi Tabeta
-
Patent number: 7692065Abstract: Clusters of plant genes that are regulated in response to one or more stress conditions are provided, as are isolated plant stress-regulated genes, including portions thereof comprising a coding sequence or a regulatory element, and to consensus sequences comprising a plant stress-regulated regulatory element. In addition, a recombinant polynucleotide, which includes a plant stress-regulated gene, or functional portion thereof, operatively linked to a heterologous nucleotide sequence, is provided, as are transgenic plants, which contain a plant stress-regulated gene or functional portion thereof that was introduced into a progenitor cell of the plant. Also provided are methods of using a plant stress-regulated gene to confer upon a plant a selective advantage to a stress condition, methods of identifying an agent that modulates the activity of a plant stress-regulated regulatory element, and methods of determining whether a plant has been exposed to a stress.Type: GrantFiled: December 9, 2005Date of Patent: April 6, 2010Assignee: The Scripps Research InstituteInventors: Jeffrey F. Harper, Joel Kreps, Xun Wang, Tong Zhu
-
Patent number: 7601885Abstract: The invention relates to compositions and methods useful for the production of transgenic plants. In particular, the invention relates to cassava vein mosaic virus (CsVMV) promoter sequences and expression cassettes containing CsVMV promoter sequences. The invention describes nucleic acid molecules, vectors and transgenic plants containing promoters derived from CsVMV promoter that are operatively linked to heterologous DNA sequences, and methods for producing transgenic plants containing these promoters.Type: GrantFiled: July 27, 2005Date of Patent: October 13, 2009Assignee: The Scripps Research InstituteInventors: Bertrand Verdaguer, Alexandre de Kochko, Roger N. Beachy, Claude Fauquet
-
Patent number: 7595051Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin ?v?3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing ?v?3 antagonists.Type: GrantFiled: October 30, 2007Date of Patent: September 29, 2009Assignee: The Scripps Research InstituteInventors: Peter C. Brooks, David A. Cheresh
-
Patent number: 7482007Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin ?v?3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing ?v?3 antagonists.Type: GrantFiled: July 15, 2004Date of Patent: January 27, 2009Assignee: The Scripps, Research InstituteInventors: Peter C. Brooks, David A. Cheresh
-
Patent number: 7473424Abstract: The present invention relates to at least one novel anti-Dengue virus antibody, including isolated nucleic acids that encode at least one anti-Dengue virus antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: January 12, 2004Date of Patent: January 6, 2009Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Paul W. H. I. Parren, Sidney Yee
-
Patent number: 7439335Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+ T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.Type: GrantFiled: April 8, 2004Date of Patent: October 21, 2008Assignee: The Scripps Research InstituteInventors: Susan R. Webb, Ola Winqvist, Lars Karlsson, Michael R. Jackson, Per A. Peterson
-
Patent number: 7402430Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+ T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.Type: GrantFiled: July 29, 2004Date of Patent: July 22, 2008Assignee: The Scripps Research InstituteInventors: Susan R. Webb, Ola Winqvist, Lars Karlsson, Michael R. Jackson, Per A. Peterson
-
Patent number: 7402314Abstract: The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.Type: GrantFiled: March 26, 1999Date of Patent: July 22, 2008Assignee: The Scripps Research InstituteInventor: Linda A. Sherman
-
Patent number: 7399743Abstract: The invention provided compositions and methods to initiate site-specific thrombosis in tumor vasculature. The present invention also provides methods for using the disclosed compositions and methods to treat tumors.Type: GrantFiled: October 24, 2002Date of Patent: July 15, 2008Assignee: The Scripps Research InstituteInventors: Cheng Liu, Thomas S. Edgington
-
Patent number: 7354586Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin ?v?3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing ?v?3 antagonists.Type: GrantFiled: July 15, 2004Date of Patent: April 8, 2008Assignee: The Scripps Research InstituteInventors: Peter C. Brooks, David A. Cheresh
-
Patent number: 7351874Abstract: The invention relates to an animal model for studying behavior related to fatty acid amide and hydrolysis of fatty acid amide. The invention provides transgenic animals in which the protein fatty acid amide hydrolase is not expressed, and methods of using such animals.Type: GrantFiled: July 30, 2002Date of Patent: April 1, 2008Assignee: The Scripps Research InstituteInventor: Benjamin F. Cravatt
-
Patent number: 7348173Abstract: The soporific activity of cis-9,10-octadecenoamide and other soporific fatty acid primary amides is neutralized by hydrolysis in the presence of fatty-acid amide hydrolase (FAAH). Hydrolysis of cis-9,10-octadecenoamide by FAAH leads to the formation of oleic acid, a compound without soporific activity. FAAH has be isolated and the gene encoding FAAH has been cloned, sequenced, and used to express recombinant FAAH. Inhibitors of FAAH are disclosed to block the hydrolase activity.Type: GrantFiled: February 26, 2004Date of Patent: March 25, 2008Assignee: The Scripps Research InstituteInventors: Norton B. Gilula, Benjamin F. Cravatt, Richrd A. Lerner